Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)--Jun 9, 2025--
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen ®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality.
The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally ( GeneReviews ), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression.
Dr. Koshizaka noted, 'We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population.'
Developing NAD+ Therapies for Rare, Age-Related Diseases
This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations.
Rob Fried, CEO of Niagen Bioscience, stated, 'Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency.'
The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations.
Vilhelm Bohr, M.D., Ph.D., D.Sc., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, 'Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population.'
Study Highlights
This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks.
Key findings include:
This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases.
For additional information on the science supporting Niagen ®, visit www.niagenbioscience.com.
About Niagen Bioscience:
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.
At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available.
Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.
Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250609224907/en/
CONTACT: Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
[email protected] Bioscience Investor Relations Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
Stephanie Carrington
(646) 277-1282
[email protected]
KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC EUROPE JAPAN CALIFORNIA
INDUSTRY KEYWORD: RESEARCH VITAMINS/SUPPLEMENTS GENETICS CLINICAL TRIALS BIOTECHNOLOGY ALTERNATIVE MEDICINE HEALTH PHARMACEUTICAL SCIENCE
SOURCE: Niagen Bioscience, Inc
Copyright Business Wire 2025.
PUB: 06/09/2025 08:32 AM/DISC: 06/09/2025 08:31 AM
http://www.businesswire.com/news/home/20250609224907/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
14 minutes ago
- Fast Company
Health is not a matter of instant gratification
In a time where almost anything you could want is just a tap away—AI-powered answers in seconds, groceries delivered within the hour, endless content streamed instantly, and real-time validation through likes and shares—it's no surprise that we've come to expect that same level of immediacy from our health. GLP-1 drugs promise rapid weight loss. Telemedicine provides patient care from the comfort of your own couch. At-home diagnostic tests deliver near-instant health insights. Social media and on-demand culture have rewired our brains to crave this kind of instant gratification, trapping many of us in a dopamine loop—that endless cycle of seeking out short-term rewards at the expense of long-term well-being. The consequences of this mindset are much deeper than we realize. In fact, the ripple effect is reshaping how we view our bodies, our health, and what it means to feel good. And it's taking a toll on our physical and mental health. The health and wellness industry, which should be offering a counterpoint to this culture, has too often played into it, promising overnight results, quick fixes, and immediate transformations. The truth is, our bodies don't operate on the same timeline as our screens. The disconnect between instant gratification and whole-body health Biological transformation is a slow and intuitive process, one that unfolds over months and years, not overnight. Yet we've been conditioned to feel like we're failing if we don't see instant results. This gap has real consequences: People abandon solutions that could meaningfully improve their health simply because they haven't delivered fast enough. In the chasing of short-term wins, we're ignoring the foundational systems that fuel long-term well-being: our stress response, hormone health, gut microbiome, and the delicate balance of nutrients that power our bodies. The rise of quick-fix wellness has only reinforced this cycle. The common thread? They all offer a dopamine hit—a fleeting sense of progress—without addressing the root causes of why we don't feel good in the first place. The problem is, quick wins rarely translate to lasting health. When we expect instant results from our bodies, we're setting ourselves up for disappointment, and that disappointment breeds distrust. We start to believe that our bodies are failing us, when in reality, it's our expectations that need recalibrating. What's more concerning is that this mindset is compounding the very issues we're trying to solve. Stress, fatigue, thinning hair, breakouts, brain fog—these are all signals that our bodies are out of balance, not problems to be hacked. But in the dopamine loop, we treat the symptoms, not the root causes. So the cycle continues. A new mindset: Longevity over quick fixes The most profound health transformations happen when we work with our bodies, not against them. This requires a radical mindset shift—one that prioritizes optimization over instant gratification and rewires the way we measure progress. What if the question wasn't 'How quickly will this work?' but instead 'How will this support the future version of me?' This is the mindset of whole-body longevity—the belief that how we feel today is deeply connected to how we'll feel five, 10, or 20 years from now. It's about setting your body up to not just feel good right now, but to stay strong and thrive for the long haul. As an industry, we have a responsibility to lead this shift. That means telling the truth about what it really takes to transform your health—that lasting change happens over months, not days. It means designing products that address the root causes of how people feel, not just surface-level symptoms. And it means empowering people to celebrate progress, not perfection, and to understand that feeling better is a journey, not a destination. The future of health is whole-body True wellbeing doesn't come from quick fixes; it comes from lasting habits. While treatments and medications can offer short-term relief, sustainable transformation requires a deeper, long-term commitment to how we live every day. Whole foods, regular movement, quality sleep, stress management, and mindful choices like reducing alcohol—these aren't trends; they're the foundation for clarity, resilience, and longevity. When these habits are supported by science-backed clinical tools, they create the conditions for real, lasting change. Health becomes something we cultivate, not hack. Imagine if we shifted the focus from fast results to long-term vitality. If success was defined not by how quickly we feel better, but by how well we're preparing our bodies and minds to thrive for decades to come. This is the future of health: slow, intentional, science-driven, and whole-body, because no part of us functions in isolation. As leaders, aligning with this vision means building not just better businesses, but a healthier world.
CBS News
17 minutes ago
- CBS News
Russian scientist from Harvard accused of smuggling frog embryos is released from federal custody
A Harvard scientist who spent months in custody on a federal smuggling charge was released Thursday after a bail hearing in Boston. Russian citizen Kseniia Petrova was stopped in February at Boston's Logan Airport by Customs and Border Protection agents as she returned on a flight from Paris. The Justice Department said in a press release that a search of her bags turned up undeclared frog embryos and embryonic samples. Petrova initially denied carrying biological materials but later admitted to it, the Justice Department said. According to a court filing by Petrova's attorney, the materials were "non-hazardous, noninfectious, and non-toxic" and she was transporting them at the request of the leader of a research group at Harvard Medical School. "Having no prior experience transporting biological samples," her attorney wrote, she "was unfamiliar with U.S. customs requirements regarding these samples. She simply placed the samples in her luggage and did not declare them to CBP at the time of her entry." But prosecutors allege that texts on her phone from a colleague show that she had been informed she would need to declare the materials. Harvard University researcher Kseniia Petrova, 30, smiles after being released on bail from federal custody at the John Joseph Moakley United States Courthouse in Boston on June 12, 2025. Leah Willingham / AP Upon discovery, CBP canceled Petrova's visa and she was taken into custody. She was sent to an ICE detention facility in Vermont and then transferred to another ICE facility in Louisiana. In May Petrova was released from ICE custody, but remained in the custody of the U.S. Marshals Service, according to The Associated Press. Petrova was a researcher at Harvard's Kirschner Lab, which focuses on cell and development biology, including cancer research. Colleagues testified on her behalf, saying she is doing valuable research and "excellent science," AP reported. "It remains difficult to understand why someone like Kseniia had to spend four months in jail. She poses no danger and has deep ties to her community," Petrova's attorney, Gregory Romanovsky, wrote in a statement to CBS News. "Her work has the potential to improve lives around the globe — including here in the United States," he added. Petrova's immigration case is ongoing, but Romanovsky said that she hasn't yet decided whether she will stay in the U.S. if she is permitted to. CBS News has also reached out to Harvard for comment.. A probable cause hearing is set for June 18.
Associated Press
28 minutes ago
- Associated Press
More at-home health tests are now available. How to know what's right for you
The doctor is in — the mailbox, that is. You can now do self-administered tests for everything from thyroid function to HIV in the privacy of your own home — and that list continues to grow, as the Food and Drug Administration recently approved the first at-home cervical cancer test. While the tests can make it easier for people to access health care and can be helpful for those who have extreme anxiety about sensitive or invasive medical exams, experts warn that most of the tests cannot replace an actual in-person visit. Here's what doctors say you can test for at home, and when you should make the trek to your physician's office. What kinds of at-home tests are available? There are two kinds at 'at-home tests.' In one type, the patient collects the sample and sends it off to a lab; the new cervical cancer test is like this. The other gives an instant result — think COVID-19 and pregnancy tests. What are the benefits of at-home tests? HIV home-testing kits can improve rates of diagnosing sexually transmitted infections in rural communities and help people who are nervous about going to the doctor to seek a sensitive test, said Dr. Joseph Cherabie, an infectious diseases specialist in St. Louis. 'You really want to get people to care as quickly as possible, but some people could be very anxious about that results as well,' Cherabie said. 'And they have very negative reactions.' Labs are required to report a positive HIV test, instead of putting the onus on the patient who took the test, Cherabie said, and and, often, the patient is matched up with HIV support services. 'If you are part of a sexual and gender minority community, going to a doctor's office can be full of a lot of historical trauma, and you may prefer to just do testing at home without anyone judging you or asking you invasive questions about your sex life,' Cherabie said. The new cervical cancer test — which tests for strains of human papillomavirus, or HPV — involves a testing swab that's like a tampon, said Dr. Susan Modesitt, a gynecologic oncologist at Emory University in Atlanta. It is not, Modesitt said, a replacement for a Pap smear, the exam in which a metal speculum is inserted in the vagina to scrape cervix cells. A doctor's visit also involves a pelvic exam, a chance to talk about abnormal bleeding — a sign of endometrial cancer — and other symptoms and issues, like menopause or STIs. 'There are so many other reasons to see your doctor and get an exam outside of a cervical cancer screening,' she said. The at-home cervical cancer test from Teal Health requires a prescription, and the company said that results are not left for the patient to interpret. I live in a rural area — can I take an at-home test? Some at-home tests can replace a trip to the doctor's office. That's especially true in rural areas, where it can be difficult to get a colonoscopy. 'The colonoscopy requires a pre-op, and you have to drive maybe 70 miles for it,' said Dr. Steven Furr, board chair of the American Academy of Family Physicians who practices in rural Alabama. 'You get anesthesia. It's actually almost like a surgical procedure in many ways. 'So, for a lot of people, that's pretty arduous. That's where an at-home test can come in handy.' But, Furr said, if your test reveals issues, you need to go to your doctor. Plus, patients should always discuss test results with their physician instead of interpreting them on their own, he said. Who shouldn't do at-home tests? If you have symptoms of what you're testing for, go to the doctor. At-home colon cancer tests aren't the right option for people with a history of colon cancer or high-risk conditions, such as inflammatory bowel disease, said Dr. Zachariah Foda, a gastroenterologist at Johns Hopkins. He added that they're also not recommended for people who are having GI symptoms. While there are tests for many things — running anywhere from $15 to $400, depending on what is being evaluated — Furr said it's essential to make sure that your test is FDA-approved so you can better trust the results. 'Anytime we get people involved in their own health care and help them understand what's going on, I think that's a good thing and it gives us a chance to talk,' he said. 'Any kind of screening is better than no screening.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
